• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血清可溶性尿激酶受体水平不能区分局灶节段性肾小球硬化与儿童肾病综合征的其他病因。

Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.

机构信息

Division of Nephrology, Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India.

Department of Pathology, All India Institute of Medical Sciences, New Delhi, India.

出版信息

Kidney Int. 2014 Mar;85(3):649-58. doi: 10.1038/ki.2013.546. Epub 2014 Jan 15.

DOI:10.1038/ki.2013.546
PMID:24429405
Abstract

In this prospective study, we measured serum levels of the soluble urokinase receptor (suPAR) in pediatric patients with nephrotic syndrome of various etiologies. Mean levels of suPAR were 3316 pg/ml in 99 patients with steroid-resistant focal segmental glomerulosclerosis and 3253 pg/ml in 117 patients with biopsy-proven minimal change disease, which were similar to that of 138 patients with steroid-sensitive nephrotic syndrome (3150 pg/ml) and 83 healthy controls (3021 pg/ml). Similar proportions of patients in each group had suPAR over 3000 pg/ml. Compared with controls, suPAR levels were significantly higher in patients with focal segmental glomerulosclerosis (FSGS) and estimated glomerular filtration rate (eGFR) under 30 ml/min per 1.73 m(2) (6365 pg/ml), congenital nephrotic syndrome (4398 pg/ml), and other proteinuric diseases with or without eGFR under 30 ml/min per 1.73 m(2) (5052 and 3875 pg/ml, respectively; both significant). There were no changes following therapy and during remission. Levels of suPAR significantly correlated in an inverse manner with eGFR (r=-0.36) and directly with C-reactive protein (r=0.20). The urinary suPAR-to-creatinine ratio significantly correlated with proteinuria (r=0.25) in 151 patients and controls. Using generalized estimating equations approach, serum suPAR significantly correlated with eGFR (coefficient=-13.75), age at sampling (2.72), and C-reactive protein (39.85). Thus, serum suPAR levels in nephrotic syndrome are similar to controls, and do not discriminate between FSGS, minimal change disease, or steroid-responsive illness.

摘要

在这项前瞻性研究中,我们测量了患有不同病因肾病综合征的儿科患者血清可溶性尿激酶受体(suPAR)的水平。99 例激素抵抗性局灶节段性肾小球硬化患者的 suPAR 平均水平为 3316pg/ml,117 例经活检证实为微小病变性肾病患者的 suPAR 平均水平为 3253pg/ml,与 138 例激素敏感性肾病综合征患者(3150pg/ml)和 83 例健康对照者(3021pg/ml)相似。各组患者中超过 3000pg/ml suPAR 的比例相似。与对照组相比,局灶节段性肾小球硬化(FSGS)和估算肾小球滤过率(eGFR)低于 30ml/min/1.73m2 的患者(6365pg/ml)、先天性肾病综合征(4398pg/ml)以及其他有或无 eGFR 低于 30ml/min/1.73m2 的蛋白尿性疾病患者(5052 和 3875pg/ml)的 suPAR 水平显著更高(均 P<0.001)。治疗前后和缓解期 suPAR 水平均无变化。suPAR 水平与 eGFR 呈负相关(r=-0.36),与 C 反应蛋白呈正相关(r=0.20)。在 151 例患者和对照组中,尿 suPAR/肌酐比值与蛋白尿显著相关(r=0.25)。采用广义估计方程方法,血清 suPAR 与 eGFR(系数=-13.75)、采样时年龄(2.72)和 C 反应蛋白(39.85)显著相关。因此,肾病综合征患者的血清 suPAR 水平与对照组相似,不能区分 FSGS、微小病变性肾病或激素反应性疾病。

相似文献

1
Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children.血清可溶性尿激酶受体水平不能区分局灶节段性肾小球硬化与儿童肾病综合征的其他病因。
Kidney Int. 2014 Mar;85(3):649-58. doi: 10.1038/ki.2013.546. Epub 2014 Jan 15.
2
The clinical pattern of nephrotic syndrome in children has no effect on the concentration of soluble urokinase receptor (suPAR) in serum and urine.儿童肾病综合征的临床模式对血清和尿液中可溶性尿激酶受体(suPAR)的浓度没有影响。
Pol Merkur Lekarski. 2018 Apr 23;44(262):183-187.
3
The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis.可溶性尿激酶型纤溶酶原激活物受体不是局灶节段性肾小球硬化的临床标志物。
Kidney Int. 2014 Mar;85(3):636-40. doi: 10.1038/ki.2013.505. Epub 2014 Jan 8.
4
[Value of soluble urokinase receptor serum levels in the differential diagnosis between idiopathic and secondary focal segmental glomerulosclerosis].[可溶性尿激酶受体血清水平在特发性与继发性局灶节段性肾小球硬化鉴别诊断中的价值]
Nefrologia. 2014;34(1):53-61. doi: 10.3265/Nefrologia.pre2013.Oct.12272.
5
Serum soluble urokinase-type plasminogen activator receptor levels and idiopathic FSGS in children: a single-center report.血清可溶性尿激酶型纤溶酶原激活物受体水平与儿童特发性 FSGS:一项单中心报告。
Clin J Am Soc Nephrol. 2013 Aug;8(8):1304-11. doi: 10.2215/CJN.07680712. Epub 2013 Apr 25.
6
CD80, suPAR and nephrotic syndrome in a case of NPHS2 mutation.CD80、suPAR 与 NPHS2 基因突变致肾病综合征
Nefrologia. 2013;33(5):727-31. doi: 10.3265/Nefrologia.pre2013.Jun.12085.
7
[Diagnostic value of soluble urokinase-type plasminogen activator receptor serum levels in adults with idiopathic nephrotic syndrome].[可溶性尿激酶型纤溶酶原激活物受体血清水平在成人特发性肾病综合征中的诊断价值]
Nefrologia. 2014;34(1):46-52. doi: 10.3265/Nefrologia.pre2013.Oct.12256.
8
Are serum suPAR determinations by current ELISA methodology reliable diagnostic biomarkers for FSGS?目前的 ELISA 方法检测血清 suPAR 是否为 FSGS 的可靠诊断生物标志物?
Kidney Int. 2014 Mar;85(3):499-501. doi: 10.1038/ki.2013.549.
9
Relationship between serum soluble urokinase plasminogen activator receptor level and steroid responsiveness in FSGS.局灶节段性肾小球硬化症中血清可溶性尿激酶型纤溶酶原激活物受体水平与类固醇反应性的关系
Clin J Am Soc Nephrol. 2014 Nov 7;9(11):1903-11. doi: 10.2215/CJN.02370314. Epub 2014 Oct 15.
10
Primary and Recurrent Focal Segmental Glomerulosclerosis Closely Link to Serum Soluble Urokinase-type Plasminogen Activator Receptor Levels.原发性及复发性局灶节段性肾小球硬化与血清可溶性尿激酶型纤溶酶原激活物受体水平密切相关。
Transplant Proc. 2015 Jul-Aug;47(6):1760-5. doi: 10.1016/j.transproceed.2015.03.048.

引用本文的文献

1
Past and future in vitro and in vivo approaches toward circulating factors and biomarkers in idiopathic nephrotic syndrome.特发性肾病综合征中循环因子和生物标志物的既往及未来体外和体内研究方法
Pediatr Nephrol. 2025 Jan 30. doi: 10.1007/s00467-024-06643-8.
2
Pathogenesis of Focal Segmental Glomerulosclerosis and Related Disorders.局灶节段性肾小球硬化及相关疾病的发病机制
Annu Rev Pathol. 2025 Jan;20(1):329-353. doi: 10.1146/annurev-pathol-051220-092001.
3
Integrins in the kidney - beyond the matrix.肾脏中的整合素——超越基质
Nat Rev Nephrol. 2025 Mar;21(3):157-174. doi: 10.1038/s41581-024-00906-1. Epub 2024 Dec 6.
4
Current understanding of the molecular mechanisms of circulating permeability factor in focal segmental glomerulosclerosis.目前对局灶节段性肾小球硬化症中循环通透因子的分子机制的认识。
Front Immunol. 2023 Sep 19;14:1247606. doi: 10.3389/fimmu.2023.1247606. eCollection 2023.
5
Rituximab in the treatment of primary FSGS: time for its use in routine clinical practice?利妥昔单抗治疗原发性局灶节段性肾小球硬化:是时候将其应用于常规临床实践了吗?
Clin Kidney J. 2023 May 24;16(8):1199-1205. doi: 10.1093/ckj/sfad122. eCollection 2023 Aug.
6
suPAR: An Inflammatory Mediator for Kidneys.可溶性尿激酶型纤溶酶原激活物受体:肾脏的一种炎症介质。
Kidney Dis (Basel). 2022 Jun 8;8(4):265-274. doi: 10.1159/000524965. eCollection 2022 Jul.
7
suPAR, a Circulating Kidney Disease Factor.可溶性尿激酶型纤溶酶原激活物受体,一种循环性肾脏疾病因子。
Front Med (Lausanne). 2021 Oct 6;8:745838. doi: 10.3389/fmed.2021.745838. eCollection 2021.
8
Recurrent Glomerulonephritis in the Kidney Allograft.肾移植受者复发性肾小球肾炎
Indian J Nephrol. 2020 Nov-Dec;30(6):359-369. doi: 10.4103/ijn.IJN_193_19. Epub 2020 Nov 30.
9
Immunopathogenesis of idiopathic nephrotic syndrome in children: two sides of the coin.儿童特发性肾病综合征的免疫发病机制:一枚硬币的两面。
World J Pediatr. 2021 Apr;17(2):115-122. doi: 10.1007/s12519-020-00400-1. Epub 2021 Mar 3.
10
Biomarkers in pediatric glomerulonephritis and nephrotic syndrome.儿童肾小球肾炎和肾病综合征的生物标志物。
Pediatr Nephrol. 2021 Sep;36(9):2659-2673. doi: 10.1007/s00467-020-04867-y. Epub 2021 Jan 3.